Literature DB >> 7594734

Reduced antifilarial IgG4 responsiveness in a subpopulation of microfilaremic persons.

S E Marley1, P J Lammie, M L Eberhard, A W Hightower.   

Abstract

Antifilarial IgG4 is a marker of active filarial infection; however, 10% of microfilaremic persons may have low levels of antifilarial IgG4. To gain insight into how persons with microfilaremia with low antifilarial IgG4 levels (< 10 micrograms/mL) differ from those with high levels (> 170 micrograms/mL), total IgG4 and IgE and filaria-specific IgE, IgG1, and IgG2 were measured by ELISA in serum samples collected from 85 microfilaremic Haitians. Persons with lower levels of antifilarial IgG4 had significantly lower total IgG4 and total IgE (P < .01), lower levels of antifilarial IgG1, IgG2, and IgE (P < .01, = .03, and < .01, respectively), and higher antigenemia and microfilaremia (P < .01) than did persons with higher levels of antifilarial IgG4. Increased antigen loads in microfilaremic persons may be associated with a down-regulation of antibody production, which extends to all isotypes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594734     DOI: 10.1093/infdis/172.6.1630

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

1.  Canine Brugia malayi microfilarial excretory/secretory protein-based antibody assay for the diagnosis of brugian filariasis in dogs.

Authors:  Poojary Vineeta Sadarama; Deepa Chirayath; Usha Narayana Pillai; N Madhavan Unny; Bindu Lakshmanan; C Sunanda
Journal:  J Parasit Dis       Date:  2019-05-30

2.  Th1-like antifilarial immune responses predominate in antigen-negative persons.

Authors:  K A Dimock; M L Eberhard; P J Lammie
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

3.  Elevated immunoglobulin E against recombinant Brugia malayi gamma-glutamyl transpeptidase in patients with bancroftian filariasis: association with tropical pulmonary eosinophilia or putative immunity.

Authors:  Edgar Lobos; Thomas B Nutman; John S Hothersall; Salvador Moncada
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.